Work

Supplementary Figure 3 from Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab

Year: 2023

Type: supplementary-materials

Abstract: Progression free survival and overall survival to pembrolizumab in ipilimumab responders vs. non-responders. (1=ipilimumab responders, 0=ipilimumab non-responders)

DOI: 10.1158/2326-6066.22537216

Authors: Amanda Shreders, Richard Joseph, Chengwei Peng, Fei Ye, Shilin Zhao, Igor Puzanov, Jeffrey A. Sosman, Douglas B. Johnson

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362551774

Cites:

Cited by:

Related to: 10